-
Sanofi's Bad End-of-the-Year Continues With Axing of Its C. Diff Drug
biospace
December 05, 2017
Sanofi?terminated an experimental Clostridium difficile vaccine?after an Independent Data Monitoring Committee concluded the Phase III trial was unlikely to hit its endpoints.
-
Sanofi Takes a $120M Hit as Potential Dengue Vaccine Blockbuster Dealt Safety Blow
biospace
December 01, 2017
Sanofi?expects to take a nearly $120 million hit after a long-term study showed use of its dengue vaccine?Dengvaxia could worsen the effects?of the mosquito-borne illness in people who had previously not been exposed to the virus.
-
World’s First Dengue Vaccine Dengvaxia into Market Plight
Mr. Nanguo
November 21, 2017
Performance of the dengue vaccine—Dengvaxia that is placed high hopes on by Sanofi is not optimistic, although the dengue is still running riot.
-
Sanofi, Novo back rare disease startup Inozyme in $49M round
americanpharmaceuticacreview
November 16, 2017
The mission is to help babies with very rare disorders caused by mineral imbalances that can lead to overcalcification of soft tissues and undermineralization of bone, and can all too often cause death.
-
Sanofi collaborates with Principia Biopharma to develop multiple sclerosis drug
biospectrumasia
November 13, 2017
Sanofi will develop Principia Biopharma Inc.’s experimental oral treatment that shows promise in multiple sclerosis (MS) and potentially other central nervous system (CNS) diseases
-
Sanofi pays $40M, commits $765M more for preclinical MS drug
fiercebiotech
November 10, 2017
Sanofi has committed up to $805 million to license multiple sclerosis drug PRN2246 from Principia Biopharma.
-
Sanofi, Principia Agree To Develop Multiple Sclerosis Drug Candidate
americanpharmaceuticacreview
November 10, 2017
Sanofi will develop Principia Biopharma experimental oral treatment that shows promise in multiple sclerosis (MS) and, potentially, other central nervous system (CNS) diseases.
-
Bay Area's Principia Biopharma Scores $765M MS Licensing Deal With Drug Giant Sanofi
biospace
November 10, 2017
SOUTH SAN FRANCISCO – A few months after striking a deal with?AbbVie, Bay Area biotech?Principia Biopharma?has signed a?deal worth up to $765 million?with?Sanofi?for the development of a multiple sclerosis drug candidate.
-
Takeda’s dengue vaccine surpasses Sanofi’s in P2 trial
pharmafile
November 08, 2017
Sanofi spent more than $1.5 billion and two decades to develop the first ever vaccine for dengue fever, only a few years after approval, however, it looks like it could be beaten, in terms of efficacy, by Takeda’s vaccine candidate.
-
Sanofi ditches IL-4/IL-13 antibody drug in lung-scarring disease
fiercebiotech
November 03, 2017
In Sanofi’s third-quarter results posted early this morning, the French Big Pharma says it is canning a phase 2 trial in idiopathic pulmonary fibrosis (IPF), following poor results from Roche and AstraZeneca.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight July 2025
